Court Backs FDA Rationale For Approving Generic Lovenox
Executive Summary
A district court shot down Sanofi-Aventis' arguments against FDA approval of Sandoz's generic Lovenox (enoxaparin)
You may also be interested in...
Lovenox Generics: FDA’s Split Opinion On ANDA Approval Fully Supported By Court
The decision will give FDA ammunition for future battles over biosimilar approvals as Sanofi’s suit against the agency is tossed out. The court notes there was a split within FDA over its five-pronged test for active ingredient sameness, which the judge sees as evidence that the issues were carefully weighed.
Generic Lovenox Battle Heats Up With Amphastar’s ANDA Approval
Momenta Pharmaceuticals and Sandoz have enjoyed approximately 14 months of de facto generic exclusivity on Sanofi’s anticoagulant Lovenox (enoxaparin), but faced with the imminent threat of competition they are trying to maintain their hold on the market through patent litigation.
Generic Lovenox Battle Heats Up With Amphastar’s ANDA Approval
Momenta Pharmaceuticals and Sandoz have enjoyed approximately 14 months of de facto generic exclusivity on Sanofi’s anticoagulant Lovenox (enoxaparin), but faced with the imminent threat of competition they are trying to maintain their hold on the market through patent litigation.